Skip to content

Investors / Press Releases


The press releases contained in this section of the website are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. Amarin disavows any obligation to update the information contained in such press releases after the date of their issuance.


Filter Releases
 
Press Releases
Date Title and Summary View
May 13, 2010
Dublin, Ireland and Mystic, CT, USA, May 13, 2010 – Amarin Corporation plc (NASDAQ: AMRN), a clinical-stage biopharmaceutical company with a focus o...
May 12, 2010
DUBLIN and MYSTIC, Conn., May 12 /PRNewswire-FirstCall/ -- Amarin Corporation plc (Nasdaq:AMRN - ...
Apr 27, 2010
Dublin, Ireland and Mystic, CT, USA , April 27, 2010 – Amarin Corporation plc (NASDAQ: AMRN) today announced that John Thero, Chief Financial Officer, is scheduled to present at Deutsche Bank Securities 35th Annual Health Care Conference.  The presentation will be made on Monday, Ma...
Mar 3, 2010
DUBLIN and MYSTIC, Conn., March 3 /PRNe...
Feb 11, 2010
DUBLIN and MYSTIC, Conn., Feb. 11 -- Amarin Corporation plc (Nasdaq: AMRN), a clinical-stage biopharmaceutical company focused on improving the treatment of cardiovascular disease, is pleased to announce the appointment of Mr. Jan...
Feb 2, 2010
DUBLIN and MYSTIC, Conn., Feb. 2 /PRNewswire-FirstCall/ -- Amarin Corporation plc (Nasdaq: AMRN) today announce...
Jan 28, 2010
Dublin, Ireland and Mystic, CT, USA, January 28, 2010 – Amarin Corporation plc (NASDAQ: AMRN), a clinical-stage biopharmaceutical company focused on improving the treatment of cardiovascular disease, today issued a special letter to its shareholders. The text of the letter, written by Dr. Declan Doogan, Amarin’s Interim...
Jan 11, 2010
San Francisco, CA, USA, January 11, 2010 – Amarin Corporation plc (NASDAQ: AMRN), a clinical-stage biopharmaceutical company focused on improving the treatment of cardiovascular disease, today announced that first patients were enrolled i...
Dec 2, 2009
Dublin, Ireland and Mystic, Connecticut, USA, December 2, 2009 – Amarin Corporation plc (NASDAQ: AMRN), a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, today announced Joseph S. Zakrzewski will join the Company’s Board of Directors as Executive Chairman effective January 1, 2010....
Nov 23, 2009
DUBLIN, Ireland, November 23, 2009 – Amarin Corporation plc (NASDAQ: AMRN) announced today that it has sent to its shareholders a Notice of the Annual General Meeting of the Company, which will be held on December 21, 2009 in Dublin, Ireland.    Copies of the Notice, togethe...
Nov 13, 2009
Ft. Lee, N.J. (November 11, 2009) – Amarin Corp.(NASDAQ: AMRN), a clinical stage pharmaceutical company with R&D operations based in Mystic, Conn., has joined SAFE-BioPharma Association, the non-profit association ...
Nov 6, 2009
DUBLIN, Ireland, November 6th, 2009 – Amarin Corporation plc (NASDAQ: AMRN) today announced the appointment of John F. Thero as the Company’s Chief Financial Officer. In this role, Mr. Thero will have broad responsibility for financial and administrative matters of the Company and be actively involved in corporate devel...
Oct 19, 2009
DUBLIN, Ireland, October 19, 2009 – Amarin Corporation plc (NASDAQ: AMRN) today announced it has closed its $70 million private placement. The transaction was led by existing investor, Fountain Healthcare Partners, on behalf of funds affiliated with other existing investors Sofinnova Ventures, Orbimed Advisors and Longitude C...
Oct 19, 2009
DUBLIN, Ireland, October 19, 2009 – Amarin Corporation plc (NASDAQ: AMRN) today announced that it has executed an agreement with Medpace, Inc. (‘Medpace’), a leading Contract Research Organization (CRO) with expertise in conducting clinical trials in cardiovascular and metabolic disease, to engage their services i...
Oct 13, 2009
DUBLIN, Ireland, October 13, 2009 – Amarin Corporation plc (NASDAQ: AMRN) today announced it has entered into a definitive agreement with several existing and new institutional and accredited investors for a $70 million private placement. The private placement of units for $70 million consists of $66.4 million in cas...
= add release to Briefcase